Topical Tranexamic Acid for Melasma: What to Expect

0
0

Among melasma treatment options, topical tranexamic acid is promising but not yet as well established as hydroquinone. A few small trials found similar improvement with the two treatments over 12 weeks, and reported less irritation with tranexamic acid. Different formulas and study designs make it hard to know how well those results apply to a serum you might buy, or whether improvement will last.

How It Compares With Other Melasma Treatment Options

Hydroquinone has long been a standard topical treatment for melasma. Tranexamic acid (TXA) is being explored as an alternative or add-on. Researchers think it may affect signals involved in pigment production, but the clinical question for you is simpler: does applying it to skin fade melasma, and how does it compare with an established option?

A randomized study by Manasa S. Janney and colleagues, published in 2019, compared a 5% TXA solution with 3% hydroquinone cream in 100 people with melasma in Bangalore, India. Participants applied their assigned treatment once daily for 12 weeks and used SPF 30 sunscreen. Their average Melasma Area and Severity Index (MASI), a measure of the area and severity of pigmentation, fell by about 27% with TXA and 26.7% with hydroquinone. The difference between the groups was not statistically significant. This suggests the treatments performed similarly in this trial; it does not prove that they are equivalent in every population or with every product.

The study also recorded irritation in 3 of 50 people using TXA (6%), compared with redness in 10 of 50 and irritation in 9 of 50 using hydroquinone. These results point to better tolerability in that particular trial, not a guarantee that TXA will suit every skin type.

A second randomized trial, led by Najmolsadat Atefi and colleagues, took place at a skin disorders clinic in Tehran, Iran, in 2015. It compared 5% topical TXA, used twice daily, with 2% hydroquinone in 60 women over 12 weeks. MASI scores decreased in both groups, with no significant difference between them. No side effects were reported in the TXA group; 10% of the hydroquinone group reported redness or irritation, a difference that was not statistically significant. The small sample means the trial cannot reliably detect uncommon side effects.

Why The Results Are Promising, But Not Conclusive

These trials tested different concentrations, schedules and vehicles: a solution once daily in one study and a different formulation twice daily in another. Hydroquinone strength also differed. That variety makes it difficult to combine the results into a dependable estimate for any one product. The studies lasted only 12 weeks, so they do not tell you whether the improvement lasts or how often melasma returns.

A 2019 review of topical and intradermal TXA studies found that most topical studies included only 13–50 people. Several reported improvement from participants’ starting scores, but comparisons with inactive vehicle were not consistently significant. Small trials can suggest a treatment is worth studying; they are less able to establish how reliably it works or identify rare harms. A marketed tranexamic acid serum for melasma may also differ from the formulations tested, so the ingredient name alone does not guarantee the same results.

What We Know About Topical Tranexamic Acid Side Effects

The small studies above reported mild irritation in some participants and no systemic effects in the TXA groups. That is reassuring for short-term use under trial conditions, but it is not enough to rule out uncommon or longer-term problems. The Bangalore trial also excluded people with a history of conditions including deep vein thrombosis, stroke and heart attack, so its safety results do not cover everyone.

Warnings about blood clots associated with oral TXA should not be transferred directly to a topical skincare product. A tablet is taken into the body; a cream or serum is applied to the skin. Those are different routes of use, and the oral risk evidence does not by itself establish the risk of topical use. But small topical trials cannot prove that every formula has no systemic absorption or that rare risks are impossible. For more on the separate evidence and considerations for tablets, read about oral tranexamic acid for melasma.

What To Consider Before Trying A Serum

Topical TXA may be an option to discuss if you are weighing alternatives to hydroquinone, especially if irritation is a concern. The trials do not establish that it works better, lasts longer or is suitable for every person. They also do not show that products from different brands are interchangeable with the study formulas. Consistent sun protection was part of the Bangalore trial, so its results should not be read as evidence for using TXA instead of sun protection.

If the pigmentation has not been diagnosed, is changing, or you are choosing between treatments, a dermatologist can help assess the situation and discuss suitable options. Seek advice from a clinician if a product causes persistent irritation.